IPCS INCHEM Home

International Agency for Research on Cancer (IARC) - Summaries & Evaluations

SULFAMETHOXAZOLE

VOL.: 24 (1980) (p. 285)

5. Summary of Data Reported and Evaluation

5.1 Experimental data

Sulfamethoxazole was tested in one experiment in rats by oral administration: it produced thyroid tumours.

No mutagenic effects were observed. Attention is drawn to the absence of studies on the teratogenicity of this compound.

5.2 Human data

Sulfamethoxazole is commonly used in the treatment of urinary-tract infections.

In one hypothesis-seeking epidemiological study, an association between sulfamethoxazole use and nasopharyngeal and cervical cancers was noted.

5.3 Evaluation

There is limited evidence for the carcinogenicity of sulfamethoxazole in experimental animals. The epidemiological data were insufficient. No evaluation of the carcinogenicity of sulfamethoxazole to humans could be made.

For definition of the italicized terms, see Preamble Evaluation.

Subsequent evaluation: Suppl. 7 (1987); Vol. 79 (2001)

Last updated: 7 April 1998 





























    See Also:
       Toxicological Abbreviations
       Sulfamethoxazole  (IARC Summary & Evaluation, Supplement7, 1987)
       Sulfamethoxazole  (IARC Summary & Evaluation, Volume 79, 2001)